Subtopic Deep Dive
Eosinophilic Esophagitis Histologic Remission
Research Guide
What is Eosinophilic Esophagitis Histologic Remission?
Eosinophilic Esophagitis Histologic Remission is the achievement of fewer than 15 eosinophils per high-power field in esophageal biopsies, serving as a primary endpoint in clinical trials for assessing treatment efficacy.
Clinical trials use <15 eos/hpf to define histologic remission in EoE, correlating it with symptom improvement. Dietary interventions achieve this endpoint in 72% of patients per meta-analysis (Arias et al., 2014, 522 citations). Biologic therapies like dupilumab induce remission rates up to 64% (Hirano et al., 2019, 432 citations). Over 10 papers from 2007-2019 establish histologic criteria and scoring systems.
Why It Matters
Histologic remission predicts sustained symptom control and reduced fibrosis risk in EoE patients, guiding FDA trial endpoints for drugs like dupilumab. Arias et al. (2014) meta-analysis shows dietary therapies induce remission superior to steroids, informing personalized treatment. Collins et al. (2016) scoring system outperforms peak eosinophil counts for monitoring, improving diagnostic accuracy in 381 children (Liacouras et al., 2005). This endpoint standardizes trial designs, accelerating approvals for biologics (Hirano et al., 2019).
Key Research Challenges
Defining Remission Thresholds
Thresholds like <15 eos/hpf vary in sensitivity across patient ages and therapies. Furuta et al. (2007) consensus set initial criteria, but Collins et al. (2016) scoring reveals limitations of peak counts alone. Validation against symptoms remains inconsistent.
Correlating Histology Symptoms
Peak eosinophil reduction often lags symptom relief, complicating endpoints. Hirano et al. (2019) trial showed dupilumab's histologic effects precede symptom scores. Surrogate biomarkers for non-invasive monitoring are underdeveloped.
Assessing Durability Long-term
Remission durability post-therapy is poorly studied beyond 1 year. Arias et al. (2014) meta-analysis reports short-term data only. Fibrosis persistence despite eosinophil clearance poses relapse risks (Collins et al., 2016).
Essential Papers
Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease
Philip O. Katz, Lauren B. Gerson, Marcelo F. Vela · 2013 · The American Journal of Gastroenterology · 1.7K citations
Gastroesophageal reflux disease (GERD) is arguably the most common disease encountered by the gastroenterologist. It is equally likely that the primary care providers will find that complaints rela...
Eosinophilic Esophagitis in Children and Adults: A Systematic Review and Consensus Recommendations for Diagnosis and Treatment
Glenn T. Furuta, Chris A. Liacouras, Margaret H. Collins et al. · 2007 · Gastroenterology · 1.7K citations
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Report of the NIAID-Sponsored Expert Panel
Unknown, Joshua A Boyce, Amal Assa'ad et al. · 2010 · Journal of Allergy and Clinical Immunology · 1.2K citations
Eosinophilic Esophagitis: A 10-Year Experience in 381 Children
Chris A. Liacouras, Jonathan M. Spergel, Eduardo D. Ruchelli et al. · 2005 · Clinical Gastroenterology and Hepatology · 868 citations
World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines
Alessandro Fiocchi, Jan Brożek, Holger J. Schünemann et al. · 2010 · World Allergy Organization Journal · 632 citations
This article was originally published online on 23 April 2010 Alessandro Fiocchi, MD, Pediatric Division, Department of Child and Maternal Medicine, University of Milan Medical School at the Mellon...
Efficacy of Dietary Interventions for Inducing Histologic Remission in Patients With Eosinophilic Esophagitis: A Systematic Review and Meta-analysis
Ángel Arias, Jesús González‐Cervera, José María Tenías et al. · 2014 · Gastroenterology · 522 citations
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis
Ikuo Hirano, Evan S. Dellon, Jennifer D. Hamilton et al. · 2019 · Gastroenterology · 432 citations
Reading Guide
Foundational Papers
Start with Furuta et al. (2007) for consensus criteria (<15 eos/hpf threshold). Follow with Liacouras et al. (2005) for 381-child experience establishing histologic patterns.
Recent Advances
Hirano et al. (2019) for dupilumab trial endpoints; Collins et al. (2016) for advanced scoring outperforming peak counts; Arias et al. (2014) for dietary meta-analysis.
Core Methods
Peak eosinophil count <15/hpf; Collins scoring (8 features: eosinophils, basal zone, surface, etc.). Dietary elimination (Spergel et al., 2012); biologics (dupilumab); PPI trial (Molina-Infante et al., 2010).
How PapersFlow Helps You Research Eosinophilic Esophagitis Histologic Remission
Discover & Search
Research Agent uses searchPapers and exaSearch to retrieve 50+ EoE papers filtered by 'histologic remission <15 eos/hpf', then citationGraph maps influences from Furuta et al. (2007, 1664 citations) to Hirano et al. (2019). findSimilarPapers expands from Arias et al. (2014) meta-analysis to uncover dietary trial comparators.
Analyze & Verify
Analysis Agent applies readPaperContent to extract remission rates from Hirano et al. (2019), then verifyResponse with CoVe cross-checks against Collins et al. (2016) scoring data. runPythonAnalysis computes meta-analytic remission odds ratios from trial tables using pandas; GRADE grading scores dietary evidence as moderate per Arias et al. (2014).
Synthesize & Write
Synthesis Agent detects gaps in long-term durability data across papers, flagging contradictions between histologic and symptom endpoints. Writing Agent uses latexEditText to draft trial comparison tables, latexSyncCitations for 10 EoE papers, and latexCompile for publication-ready reviews; exportMermaid visualizes remission pathway diagrams.
Use Cases
"Meta-analyze histologic remission rates from EoE diet trials vs biologics"
Research Agent → searchPapers('EoE histologic remission diet dupilumab') → Analysis Agent → runPythonAnalysis(pandas meta-analysis on extracted rates from Arias 2014 + Hirano 2019) → forest plot CSV output with GRADE scores.
"Write LaTeX review on EoE histologic scoring systems"
Synthesis Agent → gap detection (Collins 2016 vs Furuta 2007) → Writing Agent → latexEditText(draft sections) → latexSyncCitations(10 foundational papers) → latexCompile(PDF) with remission threshold table.
"Find code for analyzing EoE biopsy eosinophil counts"
Research Agent → paperExtractUrls(Collins 2016) → paperFindGithubRepo(eosinophil quantification) → githubRepoInspect → runPythonAnalysis(test repo script on sample biopsy data) → validated counting pipeline.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ EoE histologic papers: searchPapers → citationGraph(Furuta 2007 hub) → GRADE all interventions → structured report with remission rate tables. DeepScan applies 7-step verification to Arias et al. (2014) meta-data: readPaperContent → runPythonAnalysis(reproduce ORs) → CoVe checkpoints. Theorizer generates hypotheses on non-invasive biomarker surrogates from Collins et al. (2016) features.
Frequently Asked Questions
What defines histologic remission in EoE?
<15 eosinophils per high-power field in esophageal biopsies, per consensus (Furuta et al., 2007). Collins et al. (2016) scoring system enhances this with basal zone hyperplasia and surface changes.
What methods achieve histologic remission?
Dietary elimination induces 72% remission (Arias et al., 2014 meta-analysis). Dupilumab yields 64% rates (Hirano et al., 2019 phase 2 trial). PPI therapy responds in 50% adults (Molina-Infante et al., 2010).
What are key papers on EoE histologic remission?
Furuta et al. (2007, 1664 citations) set diagnostic consensus. Arias et al. (2014, 522 citations) meta-analyzed diets. Collins et al. (2016, 397 citations) validated scoring system; Hirano et al. (2019, 432 citations) tested biologics.
What open problems exist in histologic remission research?
Durability beyond 1 year unproven; symptom-histology correlation weak. Non-invasive surrogates lacking. Pediatric vs adult thresholds diverge (Liacouras et al., 2005).
Research Eosinophilic Esophagitis with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Eosinophilic Esophagitis Histologic Remission with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Eosinophilic Esophagitis Research Guide